TITLE

Pharmacology of Current and Investigational Human Immunodeficiency virus (HIV) Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Adults

AUTHOR(S)

Laura Waters; Marta Boffito

PUB. DATE

July 2007

SOURCE

Anti-Infective Agents in Medicinal Chemistry;2007, Vol. 6 Issue 3, p213

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Since the mid-1980s, the nucleoside reverse transcriptase inhibitors (NRTIs) have established their position as valuable antiretroviral (ARV) agents in the treatment of human immunodeficiency virus (HIV) infection. Today, NRTIs still constitute the �backbone� of highly active ARV therapy regimens. The combination of different ARV classes has enabled the goal of successful suppression of HIV replication to be achieved in most HIV infected patients and is currently standard of care to prevent the development of AIDS. The NRTIs and nucleotide reverse transcriptase inhibitors (NtRTIs) are prodrugs which require intracellular phosphorylation before they become active compounds. Apart from zidovudine they are all water soluble, and generally have a wide volume of distribution. The NRTIs undergo a three step phosphorylation process whilst the one currently available NtRTI, tenofovir, only requires two phosphorylation steps to create a clinically active diphosphate metabolite. The active phosphorylated derivatives then compete with the endogenous nucleotides for viral reverse transcriptase. Several steps in intracellular phosphorylation are rate limiting and a number of intracellular factors can affect this metabolism. There are also external influences which can affect this process. The intracellular factors include: cell type; timing within the cell cycle; levels of dideoxynucleoside analogue triphosphates (ddNTPs) created by the phosphorylation of NRTIs, and endogenous cellular deoxynucleotide triphosphates (dNTPs) which compete for substrate binding to reverse transcriptase. Importantly, drug-drug interactions involving NRTIs with other ARVs as well as with non-HIV classes of drugs are complex and may lead to the development of toxicity or limit drug efficacy. This is of particular importance with the numerous new agents in development The review will discuss the main pharmacological characteristics of the available and investigational NRTI/NtRTIs and a brief summary of the possible drug interactions which may occur between different ARV agents. An extensive discussion of drug-drug interactions between ARVs and other agents is outside the scope of this review.

ACCESSION #

25534756

Tags: HIV infections -- Treatment;  NUCLEOSIDES;  ANTIRETROVIRAL agents;  ANTIVIRAL agents;  REVERSE transcriptase

 

Related Articles

• Positioning of HIV-protease inhibitors in clinical practice. Andreoni, M.; Perno, C. F. // European Review for Medical & Pharmacological Sciences;2012, Vol. 16 Issue 1, p10 

  The availability of more than 20 drugs for the treatment of HIV infection, and the success of the current antiretroviral regimens, should not overlook the difficulty of longterm maintaining the control of viral replication. The therapy needs to be continued for decades, if not for lifetime, and...

• Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update. Peng Zhan; Xinyong Liu; Zhenyu Li // Current Medicinal Chemistry;Aug2009, Vol. 16 Issue 22, p2876 

  Currently, the long-term usage of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in HIV/AIDS patients eventually leads to the development of drug resistance and severe side effect. Therefore, it is imperative to look for the novel NNRTIs with potent and broad spectrum anti-mutant...

• Tenofovir Plus Didanosine as Nrti Backbone in HIV-Infected Subjects. Bongiovanni, Marco; Tordato, Federica // Current Medicinal Chemistry;2006, Vol. 13 Issue 23, p2789 

  Nucleoside reverse transcriptase inhibitors (NRTI) are essential components of highly active antiretroviral treatment (HAART). Although several combinations can be used as NRTI backbones, not all are associated with good virological and/or immunological results. In particular, some NRTI...

• Treating Children with HIV Infection: What We Can Do, We Should Do. Oleske, James M. // Clinical Infectious Diseases;2/15/2007, Vol. 44 Issue 4, p605 

  The article focuses on issues related to the treatment of HIV-infected children. Previous studies show that antiretroviral therapy (ART) is effective in case of children who are perinatally infected with HIV. ART includes 3 drugs--2 nucleoside reverse transcriptase inhibitors and 1 nonnucleoside...

• Clinical Implications of HIV-1 Minority Variants. Li, Jonathan Z.; Kuritzkes, Daniel R. // Clinical Infectious Diseases;Jun2013, Vol. 56 Issue 11, p1667 

  Low-frequency HIV variants are increasingly recognized as a key factor that increases the risk of HIV treatment failure. This article will provide a review of HIV minority variants, including their demonstrated clinical impact and areas of controversy.Technologic advances in human...

• Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. Breban, Romulus; Napravnik, Sonia; Kahn, James; Blower, Sally // BMC Public Health;2009 Supplement 1, Vol. 9, Special section p1 

  Background: Current measures of the clinical efficacy of antiretroviral therapy (ART) in the treatment of HIV include the change in HIV RNA in the plasma and the gain in CD4 cells. Methods: We propose new measures for evaluating the efficacy of treatment that is based upon combinations of...

• NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p610 

  The article presents information on nucleoside reverse transcriptase inhibitors, including their dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

• Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment. Pefura Yone, Eric W.; Kengne, Andr� P. // HIV/AIDS - Research & Palliative Care;2012 Part 2, Vol. 4, p181 

  An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared...

• Enhancement of dissolution rate of Efavirenz by solid dispersion technique. Kumar, Bada Pragati; Yunoos, Mohammad; Chandana, Nala; Habeeb, Mohammad; Himaja, B. // Journal of Pharmacy Research;Dec2010, Vol. 3 Issue 12, p2840 

  Efavirenz is an HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI). It is an antiretroviral agent indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, which is not soluble in water and lower absorption in gastric fluid. In order to improve the...

Read the Article